Binding of CD40L to Mac-1's i-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis-but does not affect immunity and thrombosis in mice

Circulation Research

Volumn 109, Issue 11, 2011, Pages 1269-1279

  Wolf, Dennis ^a,b   Hohmann, Jan David ^b   Wiedemann, Ansgar ^a   Bledzka, Kamila ^b,c   Blankenbach, Hermann ^a   Marchini, Timoteo ^a   Gutte, Katharina ^a   Zeschky, Katharina ^a   Bassler, Nicole ^b   Hoppe, Natalie ^a   Rodriguez, Alexandra Ortiz ^a   Herr, Nadine ^a   Hilgendorf, Ingo ^a   Stachon, Peter ^a   Willecke, Florian ^a   Duerschmied, Daniel ^a   Von Zur Muhlen, Constantin ^a   Soloviev, Dmitry A ^c   Zhang, Li ^d   Bode, Christoph ^a   Plow, Edward F ^c   Libby, Peter ^e   Peter, Karlheinz ^b   Zirlik, Andreas ^a   more..

^a UNIVERSITY OF FREIBURG   (Germany)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

atherosclerosis; CD40L; inflammation; Mac 1; peptide inhibitor

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; FIBRINOGEN RECEPTOR; PROTEIN; PROTEIN MAC 1; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BETA SHEET; BINDING SITE; CONTROLLED STUDY; IMMUNITY; INFLAMMATORY CELL; LEUKOCYTE MIGRATION; MALE; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN MOTIF; SURFACE PLASMON RESONANCE; THROMBOSIS;

AMINO ACID MOTIFS; ANIMALS; ATHEROSCLEROSIS; BLEEDING TIME; BLOOD COAGULATION; CD40 LIGAND; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; CHO CELLS; CRICETINAE; HUMANS; MACROPHAGE-1 ANTIGEN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PERITONITIS; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, LDL; RECOMBINANT FUSION PROTEINS; SURFACE PLASMON RESONANCE; THROMBOSIS;

EID: 81355148688     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.247684     Document Type: Article

References (52)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874. (Pubitemid 36019640)
2. Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, Weissleder R. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci USA. 2006;103:10340-10345. (Pubitemid 44051168)
3. Iezzi G, Sonderegger I, Ampenberger F, Schmitz N, Marsland BJ, Kopf M. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci USA. 2009;106:876-881.
4. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111. (Pubitemid 36337321)
5. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Kote-liansky VE, Flavell RA. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313-1316. (Pubitemid 29535611)
6. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394:200-203. (Pubitemid 28325976)
7. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004;22: 307-328. (Pubitemid 38680425)
8. Bavendiek U, Zirlik A, LaClair S, MacFarlane L, Libby P, Schonbeck U. Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. Arterioscler Thromb Vasc Biol. 2005;25:1244-1249. (Pubitemid 40776616)
9. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA. 2000;97:7458-7463. (Pubitemid 30431485)
10. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P. Evidence for increased collagenolysis by interstitial colla-genases-1 and-3 in vulnerable human atheromatous plaques. Circulation. 1999;99:2503-2509. (Pubitemid 29228279)
11. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integ-rin-dependent mechanism. Nat Med. 2002;8:247-252. (Pubitemid 34250102)
12. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thrombo-embolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6:114. (Pubitemid 30082329)
13. Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, Ahrens I, Ernst S, Bassler N, Missiou A, Patko Z, Aikawa M, Schonbeck U, Bode C, Libby P, Peter K. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation. 2007; 115:1571-1580. (Pubitemid 46648642)
14. Ross GD, Lambris JD. Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neu-trophils, and erythrocytes. J Exp Med. 1982;155:96-110. (Pubitemid 12209816)
15. Dunne JL, Ballantyne CM, Beaudet AL, Ley K. Control of leukocyte rolling velocity in TNF-alpha-induced inflammation by LFA-1 and Mac-1. Blood. 2002;99:336-341.
16. Altieri DC, Agbanyo FR, Plescia J, Ginsberg MH, Edgington TS, Plow EF. A unique recognition site mediates the interaction of fibrinogen with the leukocyte integrin Mac-1 (CD11b/CD18). J Biol Chem. 1990;265: 12119-12122.
17. Kanse SM, Matz RL, Preissner KT, Peter K. Promotion of leukocyte adhesion by a novel interaction between vitronectin and the beta2 integrin Mac-1 (alphaMbeta2, CD11b/CD18). Arterioscler Thromb Vasc Biol. 2004;24:2251-2256. (Pubitemid 39658025)
18. Peter K, Schwarz M, Conradt C, Nordt T, Moser M, Kubler W, Bode C. Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Circulation. 1999;100:1533-1539. (Pubitemid 29461466)
19. Ehlers R, Ustinov V, Chen Z, Zhang X, Rao R, Luscinskas FW, Lopez J, Plow E, Simon DI. Targeting platelet-leukocyte interactions: identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ibalpha. J Exp Med. 2003;198:1077-1088. (Pubitemid 37248623)
20. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198:1507-1515. (Pubitemid 37467165)
21. Diamond MS, Staunton DE, Marlin SD, Springer TA. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell. 1991;65:961-971. (Pubitemid 121001684)
22. Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ, Plow EF, Degen JL. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest. 2004;113:1596-1606. (Pubitemid 39071683)
23. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neu-trophils in vitro. J Clin Invest. 1989;83:2008-2017. (Pubitemid 19148873)
24. Zhang L, Plow EF. Identification and reconstruction of the binding site within alphaMbeta2 for a specific and high affinity ligand, NIF. J Biol Chem. 1997;272:17558-17564. (Pubitemid 27311189)
25. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem. 2000;275:21785-21788. (Pubitemid 30621742)
26. Diamond MS, Garcia-Aguilar J, Bickford JK, Corbi AL, Springer TA. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol. 1993;120: 1031-1043. (Pubitemid 23056308)
27. Takagi J, Springer TA. Integrin activation and structural rearrangement. Immunol Rev. 2002;186:141-163.
28. Zhang L, Plow EF. A discrete site modulates activation of I domains. Application to integrin alphaMbeta2. J Biol Chem. 1996;271: 29953-29957. (Pubitemid 26389632)
29. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini AM, Paludan SR, Kowalska MA, Kungl AJ, Hackeng TM, Mayo KH, Weber C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hy-perlipidemic mice. Nat Med. 2009;15:97-103.
30. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Bal-lantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP, Chavakis T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 2007;26:1129-1139.
31. Gawaz M, Langer H, May AE. Platelets in inflammation and athero-genesis. J Clin Invest. 2005;115:3378-3384.
32. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594. (Pubitemid 28157601)
33. Guiducci C, Valzasina B, Dislich H, Colombo MP. CD40/CD40L interaction regulates CD4 + CD25 + T reg homeostasis through dendritic cell-produced IL-2. Eur J Immunol. 2005;35:557-567. (Pubitemid 40331332)
34. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
35. Smook ML, Heeringa P, Damoiseaux JG, Daemen MJ, de Winther MP, Gijbels MJ, Beckers L, Lutgens E, Tervaert JW. Leukocyte CD40L deficiency affects the CD25( +) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis. 2005;183:275-282. (Pubitemid 41579278)
36. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity. 2004; 37:457-464. (Pubitemid 40123415)
37. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047-1054.
38. Khandekar SS, Silverman C, Wells-Marani J, Bacon AM, Birrell H, Brigham-Burke M, DeMarini DJ, Jonak ZL, Camilleri P, Fishman-Lobell J. Determination of carbohydrate structures N-linked to soluble CD154 and characterization of the interactions of CD40 with CD154 expressed in Pichia pastoris and Chinese hamster ovary cells. Protein Expr Purif. 2001;23: 301-310. (Pubitemid 33037799)
39. Simon SI, Green CE. Molecular mechanics and dynamics of leukocyte recruitment during inflammation. Annu Rev Biomed Eng. 2005;7: 151-185. (Pubitemid 41170187)
40. Ustinov VA, Plow EF. Delineation of the key amino acids involved in neutrophil inhibitory factor binding to the I-domain supports a mosaic model for the capacity of integrin alphaMbeta 2 to recognize multiple ligands. J Biol Chem. 2002;277:18769-18776. (Pubitemid 34952435)
41. Rieu P, Sugimori T, Griffith DL, Arnaout MA. Solvent-accessible residues on the metal ion-dependent adhesion site face of integrin CR3 mediate its binding to the neutrophil inhibitory factor. J Biol Chem. 1996;271:15858-15861. (Pubitemid 26236190)
42. Yakubenko VP, Solovjov DA, Zhang L, Yee VC, Plow EF, Ugarova TP. Identification of the binding site for fibrinogen recognition peptide gamma 383-395 within the alpha(M)I-domain of integrin alpha(M)beta2. J Biol Chem. 2001;276:13995-14003.
43. Zhang L, Plow EF. Amino acid sequences within the alpha subunit of integrin alpha M beta 2 (Mac-1) critical for specific recognition of C3bi. Biochemistry. 1999;38:8064-8071.
44. Leveille C, Bouillon M, Guo W, Bolduc J, Sharif-Askari E, El-Fakhry Y, Reyes-Moreno C, Lapointe R, Merhi Y, Wilkins JA, Mourad W. CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling. J Biol Chem. 2007;282:5143-5151. (Pubitemid 47093769)
45. Bajorath J, Chalupny NJ, Marken JS, Siadak AW, Skonier J, Gordon M, Hollenbaugh D, Noelle RJ, Ochs HD, Aruffo A. Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction. Biochemistry. 1995;34:1833-1844.
46. Bajorath J, Marken JS, Chalupny NJ, Spoon TL, Siadak AW, Gordon M, Noelle RJ, Hollenbaugh D, Aruffo A. Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry. 1995;34:9884-9892.
47. Dunne JL, Collins RG, Beaudet AL, Ballantyne CM, Ley K. Mac-1, but not LFA-1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNF-alpha-induced inflammation. J Immunol. 2003; 171:6105-6111. (Pubitemid 37467232)
48. Lo SK, Van Seventer GA, Levin SM, Wright SD. Two leukocyte receptors (CD11a/CD18 and CD11b/CD18) mediate transient adhesion to endothelium by binding to different ligands. J Immunol. 1989;143: 3325-3329. (Pubitemid 20010163)
49. Lauterbach M, O'Donnell P, Asano K, Mayadas TN. Role of TNF priming and adhesion molecules in neutrophil recruitment to intravascular immune complexes. J Leukoc Biol. 2008;83:1423-1430. (Pubitemid 351960323)
50. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endo-thelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA. 1997;94:1931-1936. (Pubitemid 27113939)
51. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuv-astatin: a prospective study of the JUPITER trial. Lancet. 2009;373: 1175-1182.
52. Patrono C, Rocca B. Nonsteroidal antiinflammatory drugs: past, present and future. Pharmacol Res. 2009;59:285-289.